WELCOME!
to IMGT/mAb-DB
THE INTERNATIONAL IMMUNOGENETICS INFORMATION SYSTEM®
IMGT
database logo
1417 entries
1234 -IG
7 -TR
47 -FPIA
68 -CPCA
61 -RPI

IMGT/mAb-DB card

Version: 2.0.4 (2023-04-14)

Citing IMGT/mAb-DB

Manso T., Kushwaha A., Abdollahi N., Duroux P., Giudicelli V. and Kossida S. Mechanisms of action of monoclonal antibodies in oncology integrated in IMGT/mAb-DB. Front Immunol., 14 (2023). DOI 10.3389/fimmu.2023.1129323

Poiron C., Wu Y., Ginestoux C., Ehrenmann, Duroux P. and Lefranc M.-P. IMGT/mAb-DB: the IMGT® database for therapeutic monoclonal antibodies. JOBIM 2010, Paper 13 (2010). Abstract PDF

Cambon M., Cherouali K., Kushwaha A., Giudicelli V., Duroux P., Kossida S. and Lefranc M.-P. IMGT/mAb-DB and IMGT/2Dstructure-DB for IMGT standard definition of an antibody: from receptor to amino acid changes. JOBIM 2018, Poster 201 (2018). Abstract PDF


IMGT/mAb-DB ID 463
INN eldelumab
INN Number 9746
INN Prop. List 109 (2013)
INN Rec. List 71 (2014)
Common name BMS-936557, MDX-1100
Proprietary name
Species Homo sapiens
IMGT receptor type IG
Format (legend)
Receptor identification IgG1 - kappa
Radiolabelled / Conjugated / Fused
IMGT/2Dstructure-DB 9746
IMGT/3Dstructure-DB
Specificity target name and species CXCL10 (chemokine C-X-C motif ligand 10, 10 kDa interferon gamma-induced protein gamma-IP10, IP-10, INP10, small inducible cytokine B10, SCYB10) [Homo sapiens]
Development Technology Medarex's UltiMAbĀ®
Origin clone species
Origin clone name

Company Bristol-Myers Squibb (Princeton NJ USA)
Expression system CHO (Chinese Hamster Ovary) cells
Application
Clinical domain Immunology
Mechanism of action
Clinical indication Rheumatoid arthritis (RA)
Development status Phase II
Regulatory agency status and year

    Company Bristol-Myers Squibb (Princeton NJ USA)
    Expression system CHO (Chinese Hamster Ovary) cells
    Application
    Clinical domain Immunology
    Mechanism of action
    Clinical indication Colitis, ulcerative (UC)
    Development status Phase II
    Regulatory agency status and year

      Clinical trials
      Authority decisions
        External links
        IMGT notes
        • Originally developed at Ability Biomedical (acquired by Medarex in 2004). In 2009, Medarex was acuired by Bristol-Myers-Squibb.
        Biosimilars
          Format legend:

          © Copyright 1995-2023 IMGT®, the international ImMunoGeneTics information system® | Terms of use | About us | Contact us | Citing IMGT
          European Commission umontpellier CNRS